Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129495 | 0.73 | — | — | |
| SCHEMBL9913287 | 0.69 | EPHX1 (0.40) | KDM4ECA2PTGS1MMP12CRBN | |
| SCHEMBL28286975 | 0.69 | — | — | |
| SCHEMBL2235123 | 0.67 | ALDH1A1 (0.36) | KDM4ECA2PTGS1MMP12CRBN | |
| SCHEMBL10138923 | 0.67 | ALDH1A1 (0.36) | — | |
| Sulfuric Acid SCHEMBL31459052 | 0.67 | CRBN (0.32) | KDM4ECA2PTGS1MMP12CRBN | |
| SCHEMBL24820865 | 0.65 | POLB (0.34) | KDM4ECA2PTGS1MMP12CRBN | |
| SCHEMBL7128936 | 0.65 | — | — | |
| SCHEMBL6363154 | 0.65 | — | — | |
| SCHEMBL124179 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302487-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2012-11-29 | — | — | US | claimed |
| EP-2494024-A1 | COMPOSITE | Revolymer Limited (GB) | 2012-09-05 | — | — | EP | claimed |
| WO-2011051681-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2011-05-05 | — | — | WO | claimed |
| US-20120302487-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| EP-2494024-A1 | COMPOSITE | Revolymer Limited (GB) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051681-A1 | COMPOSITE | REVOLYMER LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | KDM4E 1160/4885CA2 2026/4885PTGS1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.